984 related articles for article (PubMed ID: 28716027)
41. Risk Factors Associated with Survival Following Ganciclovir Prophylaxis through Day +100 in Cytomegalovirus At-Risk Pediatric Allogeneic Stem Cell Transplantation Recipients: Development of Cytomegalovirus Viremia Associated with Significantly Decreased 1-Year Survival.
Klejmont LM; Mo X; Milner J; Harrison L; Morris E; van de Ven C; Cairo MS
Transplant Cell Ther; 2024 Jan; 30(1):103.e1-103.e8. PubMed ID: 37806447
[TBL] [Abstract][Full Text] [Related]
42. Cytomegalovirus infections following renal transplantation--effects on antiviral prophylaxis: a report of the North American Pediatric Renal Transplant Cooperative Study.
Bock GH; Sullivan EK; Miller D; Gimon D; Alexander S; Ellis E; Elshihabi I
Pediatr Nephrol; 1997 Dec; 11(6):665-71. PubMed ID: 9438638
[TBL] [Abstract][Full Text] [Related]
43. Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis.
Mitsani D; Nguyen MH; Kwak EJ; Silveira FP; Vadnerkar A; Pilewski J; Crespo M; Toyoda Y; Bermudez C; Clancy CJ
J Heart Lung Transplant; 2010 Sep; 29(9):1014-20. PubMed ID: 20598582
[TBL] [Abstract][Full Text] [Related]
44. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis.
Limaye AP; Bakthavatsalam R; Kim HW; Randolph SE; Halldorson JB; Healey PJ; Kuhr CS; Levy AE; Perkins JD; Reyes JD; Boeckh M
Transplantation; 2006 Jun; 81(12):1645-52. PubMed ID: 16794529
[TBL] [Abstract][Full Text] [Related]
45. Prolonged Low-Dose Prophylaxis With Valganciclovir in Cytomegalovirus-Negative Recipients of Kidney Transplants From Cytomegalovirus-Positive Donors Allows Seroconversion and Prevents Cytomegalovirus Disease.
Halleck F; Khadzhynov D; Schrezenmeier E; Lehner L; Budde K; Staeck O
Transplant Proc; 2017 Dec; 49(10):2280-2284. PubMed ID: 29198661
[TBL] [Abstract][Full Text] [Related]
46. Low dose valganciclovir as cytomegalovirus prophylaxis in post-renal transplant recipients induced with alemtuzumab: A single-center study.
Korneffel K; Mitro G; Buschor K; Rees M; Ortiz J
Transpl Immunol; 2019 Oct; 56():101226. PubMed ID: 31344441
[TBL] [Abstract][Full Text] [Related]
47. Preemptive therapy for the prevention of cytomegalovirus disease in renal transplant recipients: our preliminary experience.
Paudice N; Mehmetaj A; Zanazzi M; Moscarelli L; Piperno R; Di Maria L; Bertoni E; Salvadori M
Transplant Proc; 2009 May; 41(4):1204-6. PubMed ID: 19460517
[TBL] [Abstract][Full Text] [Related]
48. [The significance of risk-adapted antiviral prophylaxis and modern virus diagnosis for organ survival after kidney transplantation].
Fricke L; Steinhoff J; Hartwig-Weber I; Bein G
Dtsch Med Wochenschr; 1997 May; 122(18):565-71. PubMed ID: 9190308
[TBL] [Abstract][Full Text] [Related]
49. Cytomegalovirus infection in high-risk kidney transplant recipients receiving thymoglobulin induction-a single-center experience.
Puttarajappa C; Bhattarai M; Mour G; Shen C; Sood P; Mehta R; Shah N; Tevar AD; Humar A; Wu C; Hariharan S
Clin Transplant; 2016 Sep; 30(9):1159-64. PubMed ID: 27423138
[TBL] [Abstract][Full Text] [Related]
50. Less renal allograft fibrosis with valganciclovir prophylaxis for cytomegalovirus compared to high-dose valacyclovir: a parallel group, open-label, randomized controlled trial.
Reischig T; Kacer M; Hruba P; Hermanova H; Hes O; Lysak D; Kormunda S; Bouda M
BMC Infect Dis; 2018 Nov; 18(1):573. PubMed ID: 30442095
[TBL] [Abstract][Full Text] [Related]
51. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation.
Arthurs SK; Eid AJ; Pedersen RA; Kremers WK; Cosio FG; Patel R; Razonable RR
Clin Infect Dis; 2008 Mar; 46(6):840-6. PubMed ID: 18260785
[TBL] [Abstract][Full Text] [Related]
52. CMV, EBV, JCV and BKV infection and outcome following kidney transplantation in children initiated on a corticosteroid-minimisation immunosuppressive regimen.
McCaffrey J; Bhute VJ; Shenoy M
Pediatr Nephrol; 2021 Oct; 36(10):3229-3240. PubMed ID: 33825043
[TBL] [Abstract][Full Text] [Related]
53. Systematic review of ganciclovir pharmacodynamics during the prevention of cytomegalovirus infection in adult solid organ transplant recipients.
Wong DD; van Zuylen WJ; Craig ME; Rawlinson WD
Rev Med Virol; 2019 Mar; 29(2):e2023. PubMed ID: 30556615
[TBL] [Abstract][Full Text] [Related]
54. Cytomegalovirus and Epstein-Barr virus infections among pediatric kidney transplant recipients at a center using universal Valganciclovir Prophylaxis.
Paulsen G; Cumagun P; Mixon E; Fowler K; Feig D; Shimamura M
Pediatr Transplant; 2019 May; 23(3):e13382. PubMed ID: 30786115
[TBL] [Abstract][Full Text] [Related]
55. [Clinical study of low cytomegalovirus viral load thresholds for preemptive antiviral therapy in hematopoietic cell transplant recipients].
Li L; Wang Y; Yan CH; Huang XJ
Zhonghua Nei Ke Za Zhi; 2018 Mar; 57(3):191-195. PubMed ID: 29518863
[No Abstract] [Full Text] [Related]
56. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients.
Boillat Blanco N; Pascual M; Venetz JP; Nseir G; Meylan PR; Manuel O
Transplantation; 2011 Jan; 91(2):251-5. PubMed ID: 21099744
[TBL] [Abstract][Full Text] [Related]
57. Hospitalizations for cytomegalovirus disease after renal transplantation in the United States.
Abbott KC; Hypolite IO; Viola R; Poropatich RK; Hshieh P; Cruess D; Hawkes CA; Agodoa LY
Ann Epidemiol; 2002 Aug; 12(6):402-9. PubMed ID: 12160599
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of a Cytomegalovirus Prophylaxis Protocol in Cytomegalovirus-IgG Positive Renal Transplant Recipients (R+).
Uslu A; Ari A; Simsek C; Olgut AI; Karatas M; Aykas A; Tercan IC; Tatar E
Transplant Proc; 2019 Sep; 51(7):2350-2354. PubMed ID: 31358453
[TBL] [Abstract][Full Text] [Related]
59. The impact of the prevention strategies on the indirect effects of CMV infection in solid organ transplant recipients.
Roman A; Manito N; Campistol JM; Cuervas-Mons V; Almenar L; Arias M; Casafont F; del Castillo D; Crespo-Leiro MG; Delgado JF; Herrero JI; Jara P; Morales JM; Navarro M; Oppenheimer F; Prieto M; Pulpón LA; Rimola A; Serón D; Ussetti P;
Transplant Rev (Orlando); 2014 Apr; 28(2):84-91. PubMed ID: 24602805
[TBL] [Abstract][Full Text] [Related]
60. Pharmacoepidemiology of cytomegalovirus prophylaxis in a large retrospective cohort of kidney transplant recipients with Medicare Part D coverage.
Santos CA; Brennan DC; Saeed MJ; Fraser VJ; Olsen MA
Clin Transplant; 2016 Apr; 30(4):435-44. PubMed ID: 26841129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
